Takeda, Sanofi Team Up To Explore DPP-4 Market In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda will partner with Sanofi to co-promote its DPP-4 inhibitor Nesina, which is expected to be approved in China this year.
You may also be interested in...
Lyxumia As Fourth GLP-1 To Market? Not To Worry, Says Zealand CEO
The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.
Takeda Treads Carefully With DPP-4 Late-Arrival Nesina, Plans Summer Launch
Takeda’s beleaguered Nesina (alogliptin) becomes the fourth DPP-4 inhibitor approved by FDA for diabetes; it remains to be seen whether the drug can find its place in a highly competitive space that continues to be controlled by Merck’s first-to-market blockbuster Januvia.
Takeda And Pfizer Sign A Co-Promotion Deal To Market Actos In China
Facing a looming patent cliff, Japan's Takeda made good on a pledge to dive into emerging markets by signing a co-promotion deal with Pfizer to market its type 2 Actos diabetes drug in China